Clinical Trial VICCNCPED1210


Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients with Dystrophic Epidermolysis Bullosa.

Principal Investigator(s)

Haydar Frangoul


  • Protocol No. VICCNCPED1210
  • Open Date: 02/20/2012
  • Staging: Pilot
  • Age Group: Children
  • Scope: Local
  • Objective: To determine the feasibility of using GCSF in patients with dystrophic epidermolysis bullosa.
  • Disease Sites:
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Filgrastim (GCSF)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01538862
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.